-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on June 27, the traditional Chinese medicine sector rose aga.
From the standpoint of individual stocks, Watson Pharmaceutical's daily limit, Long Shenrong rose more than 12%, Gushengtang and other stocks rose more than 5%, and Baiyunshan, Xintian Pharmaceutical, Kunyao Group, Xinbang Pharmaceutical, e.
followed su.
ro.
Specifically, among the stocks that performed well, at 9:33.
on the 27th, Watson Pharmaceuticals had an intraday daily limit of 178 yu.
As of 11:08, the stock had a turnover of 339 million, a turnover rate of 86%, and a price-earnings (TTM) of 63It is worth mentioning that the stock price of Watson Pharmaceuticals has risen by the limit 11 times in the past ye.
According to the data, the company is mainly engaged in the research and development, production and sales of chemical medicines and Chinese patent medicines, focusing on the research and development, production and sales of Chinese patent medicines and chemical medicin.
It has tablets, granules, capsules, soft capsules, powders, powders There are 11 production lines for injections, freeze-dried powder injections, APIs, traditional Chinese medicine extraction, and small-volume injectio.
As of 11:08, Long Shenrong has risen by 140%, with a quotation of 197 yuan, a turnover of 503 million, a turnover rate of 135%, and a loss in price-earnings (TT.
The company's main business is the research and development of pharmaceutical products, medical products, and health care products, as well as the production and sales of Chinese patent medicines, health foods, and AP.
In addition, Gushengtang rose by 54% and quoted a price of HK $31 The stock turnover was 986 million, the turnover rate was 14%, and the price-earnings (TTM) was a lo.
According to the data, Gushengtang is a company that focuses on basic medical care, combines new traditional Chinese medicine with modern medical methods, and creates a technology empowerment for customers that integrates offline business and online layout, covering the whole life cycle and all-scenario health manageme.
” OMO" new Chinese medicine platfo.
In terms of news, on June 24, four departments including the State Administration of Traditional Chinese Medicine issued the "Opinions on Strengthening the Work of Traditional Chinese Medicine Talents in the New Era", specifying that by 2025, all community service centers and township health centers will set up traditional Chinese medicine halls and allocate traditional Chinese medicine docto.
In recent years, the Chinese medicine industry has developed rapidly under the support of a series of favorable policies in China, and Chinese medicine services have also been welcomed by the masses at the grass-roots lev.
probl.
In order to better promote the academic progress and inheritance and innovation of traditional Chinese medicine, the "Opinions" focus on the major needs of the revitalization and development of traditional Chinese medicine, and put forward the main goal of the work of traditional Chinese medicine talents in the new era: by 2025, a talent training and evaluation system in line with the characteristics of traditional Chinese medicine will be establish.
It is basically established, the total number of talents has grown rapidly, the institutional environment has been significantly optimized, and a talent team that can basically meet the development needs of traditional Chinese medicine will be cultivat.
All community service centers and township health centers set up TCM halls and staff TCM physicia.
The "Opinions" attaches great importance to the cultivation of young top-notch talen.
It is proposed to establish and improve inclusive support measures for young talents, and set up special projects to support young talents in key talent projects, major scientific and technological projects and other engineering plans; increase the training of young talents such as outstanding Chinese medicine clinical talents and young Qihuang schola.
At the same time, give full play to the role of famous old Chinese medicine experts such as masters of Chinese medicine and famous Chinese medicine practitioners in the country, expand the scope and number of mentors and apprentices, strengthen the construction of inheritance studios, and support their recruitment and cultivation of potential young talen.
The "Opinions" make it clear that by 2030, significant progress will be made in the reform of the talent development system and mechanism, the talent echelon will be more reasonable, the scale of high-level talents will be significantly increased, the grassroots talent team will be more stable, the Chinese medicine talent center and innovation highland will be gradually built, and adapt to the high level of traditional Chinese medici.
The talent system for quality development has been basically form.
Click to enter the exhibition page
From the standpoint of individual stocks, Watson Pharmaceutical's daily limit, Long Shenrong rose more than 12%, Gushengtang and other stocks rose more than 5%, and Baiyunshan, Xintian Pharmaceutical, Kunyao Group, Xinbang Pharmaceutical, e.
followed su.
ro.
Specifically, among the stocks that performed well, at 9:33.
on the 27th, Watson Pharmaceuticals had an intraday daily limit of 178 yu.
As of 11:08, the stock had a turnover of 339 million, a turnover rate of 86%, and a price-earnings (TTM) of 63It is worth mentioning that the stock price of Watson Pharmaceuticals has risen by the limit 11 times in the past ye.
According to the data, the company is mainly engaged in the research and development, production and sales of chemical medicines and Chinese patent medicines, focusing on the research and development, production and sales of Chinese patent medicines and chemical medicin.
It has tablets, granules, capsules, soft capsules, powders, powders There are 11 production lines for injections, freeze-dried powder injections, APIs, traditional Chinese medicine extraction, and small-volume injectio.
As of 11:08, Long Shenrong has risen by 140%, with a quotation of 197 yuan, a turnover of 503 million, a turnover rate of 135%, and a loss in price-earnings (TT.
The company's main business is the research and development of pharmaceutical products, medical products, and health care products, as well as the production and sales of Chinese patent medicines, health foods, and AP.
In addition, Gushengtang rose by 54% and quoted a price of HK $31 The stock turnover was 986 million, the turnover rate was 14%, and the price-earnings (TTM) was a lo.
According to the data, Gushengtang is a company that focuses on basic medical care, combines new traditional Chinese medicine with modern medical methods, and creates a technology empowerment for customers that integrates offline business and online layout, covering the whole life cycle and all-scenario health manageme.
” OMO" new Chinese medicine platfo.
In terms of news, on June 24, four departments including the State Administration of Traditional Chinese Medicine issued the "Opinions on Strengthening the Work of Traditional Chinese Medicine Talents in the New Era", specifying that by 2025, all community service centers and township health centers will set up traditional Chinese medicine halls and allocate traditional Chinese medicine docto.
In recent years, the Chinese medicine industry has developed rapidly under the support of a series of favorable policies in China, and Chinese medicine services have also been welcomed by the masses at the grass-roots lev.
probl.
In order to better promote the academic progress and inheritance and innovation of traditional Chinese medicine, the "Opinions" focus on the major needs of the revitalization and development of traditional Chinese medicine, and put forward the main goal of the work of traditional Chinese medicine talents in the new era: by 2025, a talent training and evaluation system in line with the characteristics of traditional Chinese medicine will be establish.
It is basically established, the total number of talents has grown rapidly, the institutional environment has been significantly optimized, and a talent team that can basically meet the development needs of traditional Chinese medicine will be cultivat.
All community service centers and township health centers set up TCM halls and staff TCM physicia.
The "Opinions" attaches great importance to the cultivation of young top-notch talen.
It is proposed to establish and improve inclusive support measures for young talents, and set up special projects to support young talents in key talent projects, major scientific and technological projects and other engineering plans; increase the training of young talents such as outstanding Chinese medicine clinical talents and young Qihuang schola.
At the same time, give full play to the role of famous old Chinese medicine experts such as masters of Chinese medicine and famous Chinese medicine practitioners in the country, expand the scope and number of mentors and apprentices, strengthen the construction of inheritance studios, and support their recruitment and cultivation of potential young talen.
The "Opinions" make it clear that by 2030, significant progress will be made in the reform of the talent development system and mechanism, the talent echelon will be more reasonable, the scale of high-level talents will be significantly increased, the grassroots talent team will be more stable, the Chinese medicine talent center and innovation highland will be gradually built, and adapt to the high level of traditional Chinese medici.
The talent system for quality development has been basically form.
Click to enter the exhibition page
![benzyl N-{2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate](https://file.echemi.com/fileManage/upload/goodpicture/20210823/m20210823171124543.jpg)
